Revo Biologics announces plans to price initial public sale of stock

Piper Jaffray and Guggenheim to be joint bookrunning managers for deal

By Devika Patel

Knoxville, Tenn., June 25 – Revo Biologics, Inc. will price its initial public offering of common stock with a 30-day greenshoe option, according to a Form S-1 filed Wednesday with the Securities and Exchange Commission.

Piper Jaffray and Guggenheim Securities are the joint bookrunning managers. Roth Capital Partners and BTIG are the co-managers.

Proceeds will be used for clinical trials, sales efforts, research and development activities, working capital, operating costs and other general corporate purposes.

The biopharmaceutical company is based in Framingham, Mass. The company intends to list its common stock on the Nasdaq under the symbol “RBIO.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.